Santarus Inc

Santarus — Investor Presentation (September 2005)

27 slides from Santarus's investor presentation, Sep 27, 2005

  1. Slide 1: Santarus, Inc. (NasdaqNM: SNTS)

    NasdaqNM: SNTS

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may include forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its

  3. Slide 3: Santarus Highlights: Addressing therapeutic gaps in GI market

    Santarus Highlights Addressing therapeutic gaps in $20B+ global GI market ZEGERID(r) - Novel immediate-release omeprazole proton pump inhibitor (PPI) products Powder for Oral Suspension 20 mg launched October 2004 40 mg launched late February 2005 NDA for Capsules 20 mg & 40 mg submitted April 2005

  4. Slide 4: Santarus Highlights: Commercial target and partnerships

    Santarus Highlights Concentrated commercial target of 36,000 MDs who prescribe ~ $5.6B of PPIs Attractive co-promotion agreement with Otsuka America Pharmaceutical 400 sales reps targeting high prescribing physicians Strong intellectual property position Strategic sublicense with TAP Seasoned manage

  5. Slide 5: Evolving Upper GI Market

    Evolving Upper GI Market Delayed- release PPIs Reduces acid production - amount and duration of effect Reduces acid production - speed of effect on gastric pH Neutralizes existing acid H2-receptor antagonists Antacids Product Features

  6. Slide 6: US PPI Prescription Market

    US PPI Prescription Market AstraZeneca Prilosec(r) $0.5B TAP Prevacid(r) $3.8B J&J Aciphex(r) $1.3B Wyeth Protonix(r) $2.5B AstraZeneca Nexium(r) $3.8B Generic Omeprazole $0.6B $12.5 Billion in 2004 (Delayed-Release Products) Source: IMS Health, National Sales Perspective Audit

  7. Slide 7: US Monthly PPI Prescriptions

    US Monthly PPI Prescriptions Prilosec OTC Source: IMS Health, National Prescription Audit(tm) Moving Annual Total Rx Growth for Branded PPIs (excluding Prilosec(r)) = 5%

  8. Slide 8: US Prescription Mix for Leading Delayed-Release PPIs in 2004

    US Prescription Mix for Leading Delayed-Release PPIs in 2004 20 mg 40 mg 15 mg 30 mg 20 mg 40 mg 0.05 0.95 0 0.1 0.9 0 0.01 0.99 Source: IMS Health Nexium(r) Prevacid(r) Protonix(r)

  9. Slide 9: Unmet Clinical Needs Create Market Opportunities

    Unmet Clinical Needs Create Market Opportunities Other Market Opportunities 1/3 of GERD visits are first-time visits PPI switching rate ~15-20% Unmet Clinical Needs Breakthrough heartburn - 50% of GERD patients Nocturnal heartburn - 79% of GERD patients Special populations - pediatrics, hospital, el

  10. Slide 10: Target Patient Populations

    Target Patient Populations Unmet Need High Medium Low Market Potential Low Medium High Erosive Esophagitis 10M Ulcers 5M Daytime and Nighttime Heartburn Treatment & Prevention 25M Pediatric GERD 3M Upper GI Bleeding 4M Elderly 3M

  11. Slide 11: Zegerid Product Family

    Zegerid(r) Product Family Dose Zegerid Powder For Oral Suspension 20 mg Heartburn/GERD, Erosive Esophagitis, Duodenal Ulcer Launched Oct 2004 Zegerid Capsules 40 mg Upper GI Bleeding in Critically Ill Patients, Gastric Ulcer Launched late Feb 2005 20 mg/ 40 mg Heartburn/GERD, Erosive Esophagitis, Du

  12. Slide 12: Effect of Zegerid Antacid on pH

    Effect of Zegerid(r) Antacid on pH Antacid buffer raises pH to >7 within 1 minute pH kinetic (acid infusion) in vitro model: Effect of 20 mEq sodium bicarbonate

  13. Slide 13: Zegerid Powder for Oral Suspension: Mean Plasma Omeprazole Concentrations

    Zegerid(r) Powder for Oral Suspension 20 mg: n=35 40 mg: n=32 Mean Plasma Omeprazole Concentrations Following a Morning Dose of Zegerid Powder for Oral Suspension and Prilosec(r) on Day 1 Peak blood levels reached in 30 minutes vs. 11/2 - 2 hours

  14. Slide 14: Duration of Effect - pH > 4 Over 24 Hours

    Duration of Effect - pH > 4 Over 24 Hours Product Zegerid(r) Nexium(r) Prevacid(r) Aciphex(r) Protonix(r) Time Gastric pH > 4 30 mg/40 mg 18.6 hrs (40 mg) 16.8 hrs (40 mg) 15.8 hrs (30 mg) N/A N/A Time Gastric pH > 4 15 mg/20 mg 12.2 hrs (20 mg) 12.7 hrs (20 mg) 11.7 hrs (15 mg) 14.4 hrs (20 mg) N/A

  15. Slide 15: Zegerid Phase III Trial Results

    Zegerid(r) Phase III Trial Results * 2-sided Fisher's Exact test ** 1-sided non-inferiority analysis pH Control and Upper GI Bleeding in Critically Ill Patients 105 58 32 34 7 10 0 20 40 60 80 100 120 140 IV Cimetidine (n=181) Zegerid Oral Suspension 40 mg (n=178) Number of Patients pH ^ 4 (2 consec

  16. Slide 16: The Zegerid Difference

    The Zegerid(r) Difference Peak plasma levels in ~30 minutes 24-hour acid control Median gastric pH>4 for 18.6 hours with 40 mg dose Rapid and sustained gastric pH>4 with the first dose in critically ill patients QD (once a day) dosing any time of day Bedtime dosing provides nighttime acid control Sh

  17. Slide 17: Physician Targets: High Prescribers

    PHYSICIAN TARGETS: "High Prescribers" Less than 10% of PPI prescribing MDs $5.6 billion $1.6 billion $4.0 billion GE (10,000) High Prescribing MDs (26,000) Medium Prescribing MDs (81,000) Low Prescribing MDs (418,000) $4.9 billion $2.0 billion

  18. Slide 18: Cumulative Zegerid Prescribers

    Cumulative Zegerid(r) Prescribers 40 mg Launch

  19. Slide 19: Zegerid Monthly Prescriptions

    Zegerid(r) Monthly Prescriptions Source: IMS NPA - TRx (Retail & Mail Order)

  20. Slide 20: Expand & Partner: Path to Future Commercialization

    EXPAND & PARTNER: Path to Future Commercialization Strategic Collaborations Zegerid(r) Powder for Oral Suspension 40 mg Zegerid(r) Powder for Oral Suspension 20 mg Zegerid(r) Chewable Tablets Zegerid(r) Capsules 400 Further Expansion 230 Sales Force - GI/PCP (Santarus/Otsuka combined)

  21. Slide 21: Co-Promotion Partner: Otsuka America Pharmaceutical, Inc.

    CO-PROMOTION PARTNER: Otsuka America Pharmaceutical, Inc. Five-year, non-exclusive agreement to co- promote Zegerid(r) Powder for Oral Suspension Approximately 170 Otsuka sales representatives $15 million upfront payment received Q4 2004 High single digit royalty (for minimum number of first positio

  22. Slide 22: Strong Intellectual Property Portfolio

    Strong Intellectual Property Portfolio Exclusive worldwide license agreement with the University of Missouri Patents cover all currently marketed PPIs with antacids and other buffering agents in various liquid & solid formulations Initial issued US patents expire in 2016 Applications pending in US a

  23. Slide 23: Strategic Sublicense with TAP

    Strategic Sublicense with TAP TAP's US Prevacid(r) sales were $3.8B in 2004 Provides TAP with a differentiated product with extended patent protection $8 million upfront received in 2002 $10 million milestone received in Q1 2005 Milestones, which may exceed $100 million in total, plus royalties

  24. Slide 24: Key Financial Highlights

    Key Financial Highlights Public financings (gross proceeds) $62 million - IPO in April 2004 $66 million - Follow-on offering in July 2004 $31 million - Registered direct offering in August 2005 Otsuka upfront payment to co-promote Zegerid(r) Powder for Oral Suspension $15 million in October 2004 TAP

  25. Slide 25: Recent Key Accomplishments

    Recent Key Accomplishments Obtained FDA approval for Zegerid(r) Powder for Oral Suspension 20 mg 40 mg June 2004 Dec 2004 Built commercial organization to launch Zegerid Powder for Oral Suspension 20 mg 40 mg Oct 2004 Feb 2005 Signed co-promotion agreement with Otsuka; provides 75% increase in sales

  26. Slide 26: Future Milestones

    Future Milestones Establish Zegerid(r) brand as the only Immediate- Release oral PPI in $12.5 billion U.S. PPI market Initiate pediatric clinical studies Receive FDA decision on two NDAs in Q1 2006 Zegerid Capsules in late February 2006 Zegerid Chewable Tablets in late March 2006 Business Developmen

  27. Slide 27: Slide 27

Santarus — Investor Presentation (September 2005) on 6ix